DEST vs. ONC, OPTI, OBD, SAR, SBTX, NSCI, HEMO, SNG, OBI, and BVX
Should you be buying Destiny Pharma stock or one of its competitors? The main competitors of Destiny Pharma include Oncimmune (ONC), OptiBiotix Health (OPTI), Oxford BioDynamics (OBD), Sareum (SAR), SkinBioTherapeutics (SBTX), NetScientific (NSCI), Hemogenyx Pharmaceuticals (HEMO), Synairgen (SNG), Ondine Biomedical (OBI), and BiVictriX Therapeutics (BVX). These companies are all part of the "biotechnology" industry.
Oncimmune (LON:ONC) and Destiny Pharma (LON:DEST) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment, community ranking and dividends.
In the previous week, Destiny Pharma had 2 more articles in the media than Oncimmune. MarketBeat recorded 2 mentions for Destiny Pharma and 0 mentions for Oncimmune. Oncimmune's average media sentiment score of 0.67 beat Destiny Pharma's score of 0.34 indicating that Destiny Pharma is being referred to more favorably in the news media.
Oncimmune has a net margin of 356.25% compared to Oncimmune's net margin of 0.00%. Oncimmune's return on equity of -67.29% beat Destiny Pharma's return on equity.
35.5% of Oncimmune shares are owned by institutional investors. Comparatively, 27.3% of Destiny Pharma shares are owned by institutional investors. 28.8% of Oncimmune shares are owned by company insiders. Comparatively, 24.7% of Destiny Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Destiny Pharma received 7 more outperform votes than Oncimmune when rated by MarketBeat users. Likewise, 60.48% of users gave Destiny Pharma an outperform vote while only 59.13% of users gave Oncimmune an outperform vote.
Destiny Pharma has lower revenue, but higher earnings than Oncimmune. Destiny Pharma is trading at a lower price-to-earnings ratio than Oncimmune, indicating that it is currently the more affordable of the two stocks.
Oncimmune has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Destiny Pharma has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.
Summary
Destiny Pharma beats Oncimmune on 8 of the 15 factors compared between the two stocks.
Get Destiny Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for DEST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DEST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Destiny Pharma Competitors List
Related Companies and Tools
